Clinical Trial Update: Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) [Phase 2]

View source ↗

Summary

Phase IIa study of vorinostat (SAHA) in lower-risk myelodysplastic syndromes was terminated; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Vorinostat (SAHA) (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Myelodysplastic Syndromes, Blood Disease | Phase 2 | Status: TERMINATED | Results posted: 2010-06-22